Genomind Pharmacogenetic Testing: DNA-Guided Psychiatric Care

Harmony United Psychiatric Care now offers Genomind pharmacogenetic testing as part of our approach to mental health treatment. This testing helps our providers better understand how a patient may respond to specific psychiatric medications based on genetic factors, supporting more personalized care for patients managing depression, anxiety, bipolar disorder, ADHD, PTSD, substance use concerns, schizophrenia, and other mental health conditions.

Why does this matter? Because not everyone responds to medication the same way, finding the right fit can otherwise take months of frustrating trial and error.

Many patients experience real discouragement when a first-line treatment doesn’t bring relief. In fact, more than two-thirds of patients with major depressive disorder don’t receive complete relief from their first psychiatric medication. This gap may be explained in part by genetic differences in how the body processes certain drugs. Genomind pharmacogenetic testing, performed from a quick saliva sample, can help pinpoint which medications your body is more likely to respond well to, while also flagging medications that may carry a higher risk of side effects for you specifically.

What is Genomind Pharmacogenetic Testing

Genomind pharmacogenetic testing is a simple, non-invasive saliva-based test that analyzes genetic markers linked to how your body metabolizes and responds to psychiatric medications. It is not meant to replace a provider’s clinical judgment. Instead, it adds another meaningful layer of insight that helps reduce trial-and-error prescribing and supports more confident medication decisions.

The process itself is straightforward and typically takes just a few minutes at your appointment:

Sample collection — You provide a quick, painless saliva sample during your visit with a Harmony United provider.
Lab analysis — The sample is sent for genetic analysis, screening for markers connected to medication metabolism and side-effect risk.
Provider review — Once results are ready, your provider reviews them alongside your symptoms, medical history, and treatment goals.
Personalized planning — Your provider uses these combined insights to select or adjust medications that are more likely to work well for you specifically.

At Harmony United, our providers use these results to determine whether a patient may respond more favorably to certain antidepressants, anti-anxiety medications, opioids, or antipsychotic medications. Testing can also indicate a higher genetic risk for side effects such as weight gain or skin reactions. Interestingly, some of these genetic variants are also linked to heredity; for instance, individuals with a certain serotonin transporter gene variant common among people of Caucasian descent may respond better to non-SSRI antidepressants, while individuals of Asian ancestry with a different genetic marker may respond better to SSRIs.

What the Genomind Pharmacogenetic Testing Report May Show

The Genomind Professional PGX Express test evaluates 24 mental health-related genes, spans 10 mental health conditions, and assesses more than 130 medications, making it one of the most comprehensive pharmacogenetic tools available in psychiatric care today. Results can help inform treatment planning for:

Genomind Pharmacogenetic Testing: DNA-Guided Psychiatric Care

Why Genomind Pharmacogenetic Testing Helps

Psychiatric medications simply don’t affect everyone the same way. Some patients feel better almost immediately, while others deal with unwanted side effects or need several rounds of adjustment before finding a medication that truly fits. Genomind pharmacogenetic testing brings much-needed clarity to this process by offering insight into:

How you’re likely to metabolize antidepressants and anti-anxiety medications
Your genetic risk for side effects, such as weight gain or skin sensitivity
How your body may respond to opioids and antipsychotic medications
Genetic response patterns, for example, some individuals may respond better to non-SSRI antidepressants, while others respond better to SSRIs

Clinical research backs this up in measurable ways. In a study tracking 685 patients with a mood or anxiety disorder, 87 percent showed clinically measurable improvement within three months after their treatment was adjusted based on pharmacogenetic test results. Of that group, 62 percent went on to experience clinically significant improvement; a meaningful outcome for patients who may have otherwise spent months cycling through medications that weren’t the right fit. (Study abstract)

These findings suggest that pharmacogenetic-guided treatment can be a valuable part of a broader mental health care strategy, especially for patients who have struggled to find relief through standard prescribing alone.

Insurance Coverage and Cost

The cost of Genomind pharmacogenetic testing is covered 100 percent by Medicare. Coverage through commercial or employer insurance varies by plan, though the test remains fully reimbursable through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). If you’d like to be tested, Genomind will contact your insurance company directly and let you know your expected out-of-pocket cost ahead of time, so there are no surprises.

Next Steps

If you’re interested in mental health treatment and want to take advantage of the benefits of Genomind pharmacogenetic testing, the first step is simple: schedule an appointment with a Harmony United provider. Once you meet with your provider, they’ll arrange for the test to be done and work with you to incorporate the results directly into your treatment plan going forward.

Genomind Mental Health Map

In addition to the Professional PGX Express test, Genomind also offers the Mental Health Map, a test that provides a fuller picture of an individual’s genetic mental health predispositions. Like the pharmacogenetic test, this is done through a simple saliva sample, and it analyzes up to 38 genetic variants that may influence mental health and overall wellness. Unlike the PGX Express test, the Mental Health Map is not tied to an active provider treatment plan; it’s designed to offer personal insight and self-understanding, whether or not you’re currently working with a provider.

Results include seven in-depth, interactive reports covering:

Mood: potential predispositions include moodiness, irritability, an even temperament, Type A personality traits, reserved tendencies, low mood and energy, negative bias, and thick-skinned or thin-skinned tendencies.
Eating Behavior: Potential predispositions include late-night snacking, emotional eating, skipping breakfast, picky eating, a sweet tooth, fat cravings, and overeating.
Social Behavior: Potential predispositions include performance anxiety, sensitivity to rejection or lowered self-esteem, dwelling on embarrassment, empathy levels, lone-wolf or people-person tendencies, and trust.
Focus & Memory: Potential predispositions include inattentiveness or distractibility, decreased working or visual-spatial memory, improved muscle memory, mid-life brain fog, strategic focus, and impulsivity.
Sleep: potential predispositions include night owl versus early bird tendencies, trouble falling asleep, snoring, limb movements during sleep, and sensitivity to sleep deprivation
Substance Use & Habits: potential predispositions include increased habit-forming potential, comfort with risk-taking, becoming easily intoxicated, nicotine habit potential, and sensitivity to the effects of marijuana

The Mental Health Map also includes a 30-minute expert consultation, practical insights and recommendations, and access to NeuroFlow, a digital health tool that helps you track, measure, and manage your mental wellness over time. The Genomind Mental Health Map can be ordered here, and the cost may be eligible for reimbursement through certain FSA or HSA plans, so it is worth checking with your provider or plan administrator if you have one.